Mylan
Teva hit by patent blow upon top-selling MS drug
January 31, 2017Manufacturing and Production Mylan, Teva, generic, multiple sclerosis
Teva endured a rough ride in 2016, seeing its market value sink progressively over the course of the year. It …
Rival to EpiPen to be made available to many for free
January 23, 2017Manufacturing and Production, Sales and Marketing Kaleo, Mylan, epipen, rival
Mylan has been under scrutiny over its pricing policy with its branded EpiPen; the pressure told and led to them …
Drugstore chain CVS offers EpiPen generic for 600% cheaper
January 12, 2017Medical Communications, Sales and Marketing CVS, Mylan, epipen
The Mylan EpiPen scandal was one of last year’s most closely-followed stories, as the industry reacted with scorn to CEO …
Mylan and Biocon apply to FDA for biosimilar approval
January 12, 2017Sales and Marketing Biocon, FDA, Mylan, biosimilar, trastuzumab
Mylan, the US-based generics specialist, and Biocon, an Indian biopharmaceutical company, have applied for a biologics license application (BLA) for …
Mylan ends 2016 with spate of generics
January 3, 2017Manufacturing and Production, Sales and Marketing Mylan, generics, launch
Mylan ended a difficult year for itself by releasing a rash of generics into the market, ending the year strongly …
Mylan launches $300 generic EpiPen to calm pricing controversy
December 16, 2016Sales and Marketing Mylan, epipen
Mylan has launched a generic alternative to its flagship EpiPen auto-injector, a move to placate the outbreak of industry indignity …
Six generics companies hit by 20-state-strong lawsuit
December 16, 2016Medical Communications Heritage, Mylan, Teva
Following hot on the heels of yesterday’s news that a former CEO and president of Heritage Pharmaceuticals had been charged …
Mylan to restructure and slash around 10% of workforce
December 8, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Mylan, epipen, job losses
Mylan has submitted a regulatory filing to the Securities and Exchange Commission to announce that it would be potentially cutting …
Mylan ducks call to testify in front of Senate
November 22, 2016Manufacturing and Production, Medical Communications Department of Justice, Mylan, epipen
Mylan has avoided the call to testify in front of the Senate judiciary committee. The hearing will be convened under …
Price hiking: US pharma’s elephant in the room
October 26, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bernie Sanders, Martin Shkreli, Mylan, Sanofi, Turing Pharmaceuticals, price hikes
Mylan’s recent EpiPen price inflation scandal has reignited a seemingly never-ending debate on the power of drug companies to charge …
Mylan agrees $465m settlement over EpiPen misclassification
October 10, 2016Business Services, Medical Communications, Sales and Marketing Heather Bresch, Mylan, Price hike, epipen
In the latest scandal in the EpiPen price hike saga, the US Department of Justice has made claims that the …
“Incorrect classification” of EpiPen leads to $1 billion bill for US government
October 6, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cost, Heather Bresch, Misclassification, Mylan, Price hike, classification, epipen, price, scandal
Mylan’s EpiPen woes show no sign of abating after CMS (Centers for Medicare and Medicaid Services) released figures that show …
Mylan’s promised half-price EpiPen not available until year’s end
October 5, 2016Research and Development, Sales and Marketing Mylan, epipen
Consumers may have to wait until the end of the year for the half-price EpiPen, months after Mylan originally promised …
Price-hiked EpiPen profits 66% higher than Mylan CEO claimed
September 27, 2016Business Services, Manufacturing and Production, Sales and Marketing Heather Bresch, Mylan, epipen
In the latest development in the Mylan EpiPen scandal, it has been discovered that CEO Heather Bresch lied to US …
EpiPen CEO appears before US lawmakers to defend “sickening” price hikes
September 22, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Heather Bresch, Mylan, epipen
Disgraced Mylan CEO Heather Bresch (pictured) has appeared before US lawmakers to defend the company’s now infamous and much-maligned inflation …
Latest content
ESTEVE CDMO adds $17.5m to Illinois expansion
Brenntag and dsm-firmenich expand biopharma vitamin partnership
